AY
AYTU.US Aytu BioScience Inc
- Market cap
- USD 19.6M
- P/E
- -
- P/B
- 0.55x
- ROE
- -40.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is AYTU.US undervalued?
Graham numberThe Graham number of Aytu BioScience Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aytu BioScience Inc fundamental analysis
No fundamental analysis for Aytu BioScience Inc yet.
Aytu BioScience Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years o…
Full company profileAytu BioScience Inc financial statements
Aytu BioScience Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 3.22M | 3.66M | 7.32M | 27.6M | 65.6M | 96.7M | 107M | 65.2M | 66.4M | 57.6M |
| Gross Profit | 1.80M | 1.61M | 5.12M | 19.4M | 29.2M | 50.3M | 66.6M | 49.1M | 45.8M | 36.8M |
| Operating Income | -20.1M | -19.7M | -16.8M | -21.1M | -58.9M | -110M | -17.1M | -1.59M | -7.83M | -8.32M |
| EBITDA | -15.6M | -15.3M | -14.1M | -12.2M | -29.0M | -28.0M | -3.27M | 1.41M | -4.67M | -4.38M |
| Net Income | -22.5M | -10.2M | -47.2M | -13.6M | -58.3M | -109M | -17.1M | -15.8M | -13.6M | -14.3M |
| EPS | -192,379 | -3,061 | -1,210 | -60 | -69 | -74 | -5.11 | -2.86 | -2.16 | -1.16 |
| Balance Sheet | ||||||||||
| Total Assets | 15.0M | 21.1M | 34.7M | 153M | 266M | 138M | 138M | 119M | 124M | 105M |
| Total Liabilities | 11.0M | 7.64M | 27.6M | 57.8M | 128M | 93.3M | 98.5M | 91.1M | 105M | 69.7M |
| Shareholders' Equity | 4.00M | 13.4M | 7.09M | 95.0M | 138M | 44.3M | 39.4M | 27.7M | 19.0M | 35.3M |
| Cash & Short-term Investments | 802K | 7.01M | 11.0M | 48.1M | 49.6M | 19.4M | 23.0M | 20.0M | 31.0M | 26.3M |
| Total Debt | - | - | - | 12.5M | 31.0M | 18.2M | 30.4M | 16.4M | 22.9M | 18.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -13.8M | -15.9M | -13.8M | -28.4M | -26.0M | -28.8M | -5.13M | -1.39M | -1.94M | 3.28M |
| Capital Expenditure | 112K | 74.7K | 59.8K | 5.85M | 2.34M | 2.34M | 0.00 | 329K | 3.23M | 29.0K |
| Free Cash Flow | -13.9M | -16.0M | -13.9M | -28.4M | -26.0M | -28.8M | -5.13M | -1.72M | -5.17M | 3.25M |
| Ratios | ||||||||||
| ROE | -562.7% | -75.9% | -665.5% | -14.3% | -42.4% | -245.5% | -43.3% | -57.2% | -71.5% | -40.4% |
| ROA | -150.1% | -48.4% | -135.8% | -8.9% | -21.9% | -79.0% | -12.4% | -13.3% | -10.9% | -13.6% |
| Net Profit Margin | -698.7% | -278.4% | -644.3% | -49.3% | -88.8% | -112.5% | -15.9% | -24.3% | -20.4% | -24.8% |
| Debt to Equity | - | - | - | 0.13x | 0.23x | 0.41x | 0.77x | 0.59x | 1.21x | 0.51x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aytu BioScience Inc dividends
Aytu BioScience Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:20 on Jan 6, 2023.
Who owns Aytu BioScience Inc
- Insiders 8.26%
- Institutions 35.98%
- Public & others 55.77%
- Shares outstanding 10.9M
- Free float 7.69M
Top funds holding AYTU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 169K | 1.56% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 78.4K | 0.72% | +61.23% | Sep 2026 |
| Fidelity Series Total Market Index | 14.1K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 9.76K | 0.09% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 6.25K | 0.06% | +52.37% | Sep 2026 |
| DFA US Core Equity Class F | 5.52K | 0.05% | 0.00% | Aug 2026 |
| DFA U.S. Vector Equity I | 5.48K | 0.05% | 0.00% | Sep 2026 |
| DFA US Vector Equity Class F | 5.32K | 0.05% | 0.00% | Aug 2026 |
| JNL/DFA US Core Equity A | 4.72K | 0.04% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 4.70K | 0.04% | 0.00% | Oct 2026 |
| DFA US Sustainability Core 1 | 4.64K | 0.04% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 4.40K | 0.04% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 2 ETF | 4.12K | 0.04% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 1 ETF | 2.15K | 0.02% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 1.74K | 0.02% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 2 Instl | 1.71K | 0.02% | 0.00% | Sep 2026 |
| Bridgeway Omni Small-Cap Value N | 1.50K | 0.01% | 0.00% | Jun 2026 |
| Dimensional US Core Equity USD Acc | 1.34K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding AYTU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2.17M | 20.00% | +100.00% | Jun 2026 |
| Stonepine Capital Management Llc | 913K | 8.40% | +15.23% | Jun 2026 |
| Awm Investment Company Inc | 620K | 5.70% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 261K | 2.40% | 0.00% | Jun 2026 |
| CROWN ADVISORS MANAGEMENT, INC. | 200K | 1.84% | +37.93% | Jun 2026 |
| Diadema Partners LP | 149K | 1.37% | -57.93% | Jun 2026 |
| Two Sigma Investments LLC | 105K | 0.97% | -13.65% | Jun 2026 |
| Renaissance Technologies Corp | 105K | 0.96% | +11.84% | Jun 2026 |
| Geode Capital Management, LLC | 93.6K | 0.86% | +1.09% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 50.0K | 0.46% | +10.41% | Sep 2026 |
| Citadel Advisors Llc | 49.4K | 0.45% | +34.13% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 47.0K | 0.43% | 0.00% | Jun 2026 |
| Persistent Asset Partners Limited | 38.0K | 0.35% | -59.11% | Jun 2026 |
| Northern Trust Corp | 27.9K | 0.26% | +45.68% | Jun 2026 |
| Bellevue Asset Management, LLC | 25.0K | 0.23% | 0.00% | Jun 2026 |
| BlackRock Inc | 22.8K | 0.21% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 21.4K | 0.20% | -0.77% | Jun 2026 |
| Acadian Asset Management LLC | 10.2K | 0.09% | 0.00% | Jun 2026 |
| Daytona Street Capital LLC | 10.0K | 0.09% | 0.00% | Jun 2026 |
| UBS Group AG | 2.38K | 0.02% | +42.93% | Jun 2026 |
Aytu BioScience Inc company profile
- Company name
- Aytu BioScience Inc
- Ticker
- AYTU.US
- Exchange
- USA Stocks
- Listed since
- Feb 1, 2017
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 75
- Fiscal year end
- June
- Address
- 7900 East Union Avenue, Denver, CO, United States, 80237
- Phone
- 720 437 6580
- Website
- aytubio.com
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Aytu BioScience Inc management
6- Mr. Joshua R. DisbrowCEO & Director · born 1975
- Mr. Ryan J. Selhorn CPACFO, Corporate Secretary & Treasurer · born 1982
- Mr. Jarrett T. Disbrow Ph.D.Chief Business Officer · born 1975
- Mr. Greg PyszczymukaChief Commercial Officer · born 1979
- Ms. Margaret CabanoVice President of Operations
- Dr. Gerwin Westfield Ph.D.Senior Vice President of Scientific Affairs